Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients – 30 months follow‐up

Background There are no data on the effect of low‐dose anticoagulation as secondary prophylaxis for venous thromboembolism (VTE) in cancer patients. We assessed the efficacy and safety of low‐dose apixaban for 30 months, after initial 6 months of full‐dose treatment. Methods We included 298 patients...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of thrombosis and haemostasis 2022-05, Vol.20 (5), p.1166-1181
Hauptverfasser:	Larsen, Trine‐Lise, Garresori, Herish, Brekke, Jorunn, Enden, Tone, Frøen, Hege, Jacobsen, Eva Marie, Quist‐Paulsen, Petter, Porojnicu, Alina Carmen, Ree, Anne Hansen, Torfoss, Dag, Osvik Velle, Elin, Skuterud Wik, Hilde, Ghanima, Waleed, Sandset, Per Morten, Dahm, Anders Erik Astrup
Format:	Artikel
Sprache:	eng
Schlagworte:	Anticoagulants Anticoagulants - therapeutic use apixaban Bleeding Cancer clinical trial Disease prevention Follow-Up Studies Hemorrhage - epidemiology Humans neoplasms Neoplasms - complications Neoplasms - drug therapy Patients Prophylaxis Pyrazoles Pyridones Thromboembolism venous thromboembolism Venous Thromboembolism - diagnosis Venous Thromboembolism - epidemiology Venous Thromboembolism - prevention & control
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!